CMT Research Foundation

The CMT Research Foundation is a patient-led non-profit organization based in Atlanta, Georgia. Established in 2018, it focuses on funding translational research to develop treatments and potential cures for Charcot-Marie-Tooth disease.

Cleary Simpson

CEO and Founding Board Member

3 past transactions

Augustine Therapeutics

Series A in 2025
Augustine Therapeutics N.V. is a biopharmaceutical company based in Gent, Belgium, focused on developing innovative therapies for patients suffering from Charcot-Marie-Tooth disease (CMT) and other neuromuscular disorders. Founded in 2019, the company is engaged in two drug discovery programs aimed at identifying novel selective HDAC6 inhibitors. These compounds are designed to prevent nerve degeneration and facilitate the repair of peripheral myelin and axons. Through its research and development efforts, Augustine Therapeutics seeks to enhance the quality of life for patients affected by these debilitating conditions.

ReviR Therapeutics

Series A in 2024
ReviR Therapeutics is a genomics-focused company that specializes in the development of RNA therapeutics aimed at treating cancer, rare genetic disorders, and infectious diseases. The company utilizes an artificial intelligence-driven platform to enhance the discovery of novel RNA-targeting medicines, thereby facilitating the delivery of innovative therapies to a wide patient population. ReviR Therapeutics combines advanced computational techniques with its expertise in RNA biology, positioning itself as a leader in the evolving field of RNA-based therapeutics.

Asha Therapeutics

Asha Therapeutics focuses on developing treatments for neurodegenerative diseases such as Parkinson's and Alzheimer's. It employs a unique mito-centric approach, aiming to restore cellular function by re-engineering mitochondrial machinery.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.